Cargando…

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

BACKGROUND: Although in recent years, the introduction of novel chemotherapy protocols has improved the outcome of T cell acute lymphoblastic leukemia (T-ALL) patients, refractory and/or relapsing disease remains a foremost concern. In this context, a major contribution was provided by the introduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lonetti, Annalisa, Cappellini, Alessandra, Bertaina, Alice, Locatelli, Franco, Pession, Andrea, Buontempo, Francesca, Evangelisti, Camilla, Evangelisti, Cecilia, Orsini, Ester, Zambonin, Laura, Neri, Luca Maria, Martelli, Alberto Maria, Chiarini, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075755/ https://www.ncbi.nlm.nih.gov/pubmed/27776559 http://dx.doi.org/10.1186/s13045-016-0344-4

Ejemplares similares

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors
por: Lonetti, Annalisa, et al.
Publicado: (2015)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
por: Bressanin, Daniela, et al.
Publicado: (2012)

Therapeutic targeting of CK2 in acute and chronic leukemias
por: Buontempo, F, et al.
Publicado: (2018)

Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics
por: Evangelisti, Cecilia, et al.
Publicado: (2014)

The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia
por: Chiarini, Francesca, et al.
Publicado: (2020)

The Cutting Edge: The Role of mTOR Signaling in Laminopathies
por: Chiarini, Francesca, et al.
Publicado: (2019)

B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
por: Ratti, Stefano, et al.
Publicado: (2020)

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2010)

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
por: Martelli, Alberto M., et al.
Publicado: (2012)

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
por: Chiarini, Francesca, et al.
Publicado: (2012)

Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
por: Cooper, Todd M
Publicado: (2007)

Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia
por: Reilly, Kelly M, et al.
Publicado: (2009)

Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML
por: Lonetti, Annalisa, et al.
Publicado: (2020)

Rhabdomyolysis induced by nelarabine
por: Späth, Christian, et al.
Publicado: (2022)

GSK-3β: A key regulator of breast cancer drug resistance
por: Martelli, Alberto M, et al.
Publicado: (2014)

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia
por: Shimony, Shai, et al.
Publicado: (2022)

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias
por: Martelli, Alberto M., et al.
Publicado: (2020)

Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
por: Martelli, Alberto M., et al.
Publicado: (2022)

Nelarabine Associated Myotoxicity and Rhabdomyolysis
por: Haider, Mahnur, et al.
Publicado: (2015)

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells
por: Evangelisti, Camilla, et al.
Publicado: (2020)

The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology
por: Martelli, Alberto M., et al.
Publicado: (2010)

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine
por: Rothenburger, Tamara, et al.
Publicado: (2020)

Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report
por: Utsumi, Akari, et al.
Publicado: (2022)

MRI findings of nelarabine‐related rhabdomyolysis in a patient with refractory T‐cell acute lymphoblastic leukemia
por: Mukai, Daiki, et al.
Publicado: (2023)

Nelarabine in the Treatment of Refractory T-Cell Malignancies
por: Roecker, Andrew M., et al.
Publicado: (2010)

Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene
por: Masetti, Riccardo, et al.
Publicado: (2017)

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients
por: Martelli, Alberto M., et al.
Publicado: (2013)

Clinical Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
por: Tisi, Maria Chiara, et al.
Publicado: (2015)

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases
por: Molle, Ingolf, et al.
Publicado: (2022)

IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma
por: Folgiero, Valentina, et al.
Publicado: (2016)

MYCN is a novel oncogenic target in pediatric T-cell Acute Lymphoblastic Leukemia
por: Astolfi, Annalisa, et al.
Publicado: (2013)

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria‐related disorders
por: Evangelisti, Camilla, et al.
Publicado: (2016)

Targeted Therapies for Pediatric AML: Gaps and Perspective
por: Lonetti, Annalisa, et al.
Publicado: (2019)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Antigene MYCN Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance
por: Bortolotti, Sonia, et al.
Publicado: (2023)

Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma
por: Chiarini, Francesca, et al.
Publicado: (2022)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nd6n13oan7b668mefhqtgd64qe